1. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377(9768):849-862.
2. Brauburger K, Hume AJ, Mühlberger E, Olejnik J. Forty-five years of marburg virus research. Viruses. 2012;4(10):1878-1927.
3. World Health Organization. Ebola virus disease. Fact Sheet. 2021.
4. Kuhn JH, et al. ICTV Virus Taxonomy Profile: Filoviridae. J Gen Virol. 2019;100(6):911-912.
5. Goldstein T, et al. The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nat Microbiol. 2018;3(10):1084-1089.
6. Slenczka W, Klenk HD. Forty years of marburg virus. J Infect Dis. 2007;196 Suppl 2:S131-5.
7. Amarasinghe GK, et al. Taxonomy of the order Mononegavirales: update 2018. Arch Virol. 2018;163(8):2283-2294.
8. Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med. 2004;10(12 Suppl):S110-21.
9. Sanchez A, et al. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res. 1993;29(3):215-240.
10. Mohan GS, Li W, Ye L, Compans RW, Yang C. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog. 2012;8(12):e1003065.
11. Basler CF, et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol. 2003;77(14):7945-7956.
12. Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for
filovirus budding. Proc Natl Acad Sci U S A. 2000;97(25):13871-13876.
13. Lee JE, Saphire EO. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol. 2009;4(6):621-635.
14. Reid SP, Leung LW, Hartman AL, et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol. 2006;80(11):5156-5167.
15. Piercy TJ, Smither SJ, Steward JA, Eastaugh L, Lever MS. The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol. J Appl Microbiol. 2010;109(5):1531-1539.
16. Alvarez CP, et al. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol. 2002;76(13):6841-6844.
17. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science. 2005;308(5728):1643-1645.
18. Hoenen T, Groseth A, Falzarano D, Feldmann H. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med. 2006;12(5):206-215.
19. Noda T, et al. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol. 2002;76(10):4855-4865.
20. Leroy EM, et al. Fruit bats as reservoirs of Ebola virus. Nature. 2005;438(7068):575-576.
21. Dowell SF, et al. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179 Suppl 1:S87-91.
22. Deen GF, et al. Ebola RNA persistence in semen of Ebola virus disease survivors – final report. N Engl J Med. 2017;377(15):1428-1437.
23. Fowler RA, et al. Caring for critically ill patients with ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med. 2014;190(7):733-737.
24. Bwaka MA, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis. 1999;179 Suppl 1:S1-7.
25. Rollin PE, et al. Hematologic findings in patients with Ebola hemorrhagic fever. J Infect Dis. 1999;179 Suppl 1:S18-23.
26. Towner JS, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol.
2004;78(8):4330-4341.
27. Niikura M, et al. Detection of Ebola viral antigen by enzyme-linked immunosorbent assay using a novel monoclonal antibody to nucleoprotein. J Clin Microbiol. 2001;39(9):3267-3271.
28. Elliott LH, Kiley MP, McCormick JB. Descriptive analysis of Ebola virus proteins. Virology. 1985;147(1):169-176.
29. Ksiazek TG, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo,
1995. J Infect Dis. 1999;179 Suppl 1:S177-87.
30. West TE, von Saint André-von Arnim A. Clinical presentation and management of severe Ebola virus disease. Ann Am Thorac Soc. 2014;11(9):1341-1350.
31. Mulangu S, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293-2303.
32. Sissoko D, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): A historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med.
2016;13(3):e1001967.
33. World Health Organization. Infection prevention and control guidance for care of patients with suspected or confirmed Filovirus haemorrhagic fever in health-care settings, with focus on
Ebola. 2014.
34. Henao-Restrepo AM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-rando-
mised trial (Ebola Ça Suffit!). Lancet. 2017;389(10068):505-518.
35. Anywaine Z, et al. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized
clinical trial in Uganda and Tanzania. J Infect Dis. 2019;220(1):46-56.
36. Kinsman J. “A time of fear”: local, national, and international responses to a large Ebola outbreak in Uganda. Global Health. 2012;8:15.
37. Varkey JB, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med. 2015;372(25):2423-2427.
38. Woolsey C, Geisbert TW. Current state of Ebola virus vaccines: A snapshot. PLoS Pathog. 2021;17(12): e1010078.
ROBOVİRÜSLER
KAYNAKLAR
1. Schmaljohn C, & Hjelle B. Hantaviruses: a global disease problem. Emerg Infect Dis. 1997; 3: 95–104.
2. Jonsson C. B., Figueiredo L. T., & Vapalahti O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin Microbiol Rev. 2010; 23: 412–441.
3. Vaheri A., Strandin T., Hepojoki J., ve ark. Uncovering the mysteries of hantavirus infections. Nat Rev Microbiol. 2013; 11: 539–550.
4. Lee HW, Lee PW, & Johnson KM. Isolation of the etiologic agent of Korean Hemorrhagic Fever. J Infect Dis. 1978; 137: 298–308.
5. Lee HW, & van der Groen G. Hemorrhagic fever with renal syndrome. Prog Med Virol. 1989; 36: 62–102.
6. Duchin JS, Koster FT, Peters CJ, ve ark. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. New Eng J Med. 1994; 330: 949–955.
7. Bradfute SB, Calisher CH, Klempa B ve ark. ICTV Virus Taxonomy Profile: Hantaviridae. J Gen Virol. 2024; PMID: 38587456.
8. Kruger, D. H., Figueiredo, L. T., Song, J. W., & Klempa, B. (2015). Hantaviruses—globally emerging pathogens. Journal of Clinical Virology, 64, 128–136.
9. Clement, J., Maes, P., Lagrou, K., Van Ranst, M., & Lameire, N. (2012). A unifying hypothesis and a single name for a complex globally emerging infection: hantavirus disease. European
Journal of Clinical Microbiology & Infectious Diseases, 31(1), 1–5.
10. Vapalahti, O., Mustonen, J., Lundkvist, Å., Henttonen, H., Plyusnin, A., & Vaheri, A. (2003). Hantavirus infections in Europe. The Lancet Infectious Diseases, 3(10), 653–661.
11. Avšič-Županc, T., Saksida, A., & Korva, M. (2019). Hantavirus infections. Clinical Microbiology and Infection, 21S, e6–e16.
12. Padula, P. J., Edelstein, A., Miguel, S. D., López, N. M., Rossi, C. M., & Rabinovich, R. D. (1998). Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for per-
son-to-person transmission of Andes virus. Virology, 241(2), 323–330.
13. Williams, R. J., Bryan, R. T., Mills, J. N., Palma, R. E., Vera, I. R., De Velasquez, F., … & Peters, C. J. (1997). An outbreak of hantavirus pulmonary syndrome in western Paraguay. American
Journal of Tropical Medicine and Hygiene, 57(3), 274–282.
14. Guo, W. P., Lin, X. D., Wang, W., Tian, J. H., Cong, M. L., Zhang, H. L., … & Zhang, Y. Z. (2013). Phylogeny and origins of hantaviruses harbored by bats, insectivores, and rodents. PLoS
Pathogens, 9(2), e1003159.
15. Hepojoki, J., Strandin, T., Lankinen, H., & Vaheri, A. (2012). Hantavirus structure–molecular interactions behind the scene. Journal of General Virology, 93(Pt 8), 1631–1644.
16. Kukkonen, S. K., Vaheri, A., & Plyusnin, A. (2005). L protein, the RNA-dependent RNA polymerase of hantaviruses. Archives of Virology, 150(3), 533–556.
17. Lober, C., Anheier, B., Lindow, S., Klenk, H. D., & Feldmann, H. (2001). The Hantaan virus glycoprotein precursor is cleaved at the conserved pentapeptide WAASA. Virology, 289(2),
224–229.
18. Kaukinen, P., Vaheri, A., & Plyusnin, A. (2005). Hantavirus nucleocapsid protein: a multifunctional molecule with both housekeeping and ambulatory duties. Archives of Virology, 150(9),
1693–1713.
19. Gavrilovskaya, I. N., Shepley, M., Shaw, R., Ginsberg, M. H., & Mackow, E. R. (1998). β3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proceedings of the
National Academy of Sciences, 95(12), 7074–7079.
20. Walter, C. T., & Barr, J. N. (2011). Recent advances in the molecular and cellular biology of bunyaviruses. Journal of General Virology, 92(Pt 11), 2467–2484.
21. Kallio, E. R., Klingström, J., Gustafsson, E., Manni, T., Vaheri, A., Henttonen, H., … & Lundkvist, Å. (2006). Prolonged survival of Puumala hantavirus outside the host: evidence for indirect
transmission via the environment. Journal of General Virology, 87(Pt 8), 2127–2134.
22. Jonsson, C. B., & Schmaljohn, C. S. (2001). Replication of hantaviruses. Curr Top Microbiol Immunol.; 256: 15–32.
23. Jin M, Park J, Lee S, Park B ve ark. Hantaan virus enters cells by clathrin-dependent receptor-mediated endocytosis. Virology. 2002; 294: 60-69.
24. Reguera J, Weber F, Cusack S. Bunyaviridae RNA polymerases (L-protein) have an N-terminal, influenza-like endonuclease domain, essential for viral cap-snatching. Proceed Nat Acad Sci.
2010; 107: 4454-4459.
25. Watson, D. C., Sargianou, M., Papa, A., Chra, P., Starakis, I., & Panos, G. (2014). Epidemiology of Hantavirus infections in humans: a comprehensive, global overview. Critical Reviews in
Microbiology, 40(3), 261–272.
26. Zhang, Y. Z., Zou, Y., Fu, Z. F., & Plyusnin, A. (2010). Hantavirus infections in humans and animals, China. Emerging Infectious Diseases, 16(8), 1195–1203.
27. Heyman, P., Ceianu, C. S., Christova, I., Tordo, N., Beersma, M., João Alves, M., … & Lundkvist, Å. (2011). A five-year perspective on the situation of haemorrhagic fever with renal syndrome
and status of the hantavirus reservoirs in Europe, 2005-2010. Eurosurveillance, 16(36), 19961.
28. Klempa, B. (2009). Hantaviruses and climate change. Clinical Microbiology and Infection, 15(6), 518–523.
29. Mills, J. N., Yates, T. L., Childs, J. E., Parmenter, R. R., Ksiazek, T. G., Rollin, P. E., & Peters, C. J. (1995). Guidelines for working with rodents potentially infected with hantavirus. Journal of
Mammalogy, 76(3), 716–722.
30. Kavukçu S, Türkmen M, Salman Ş ve ark. What is the risk of nephropathy associated with Hantavirus in Aegean region. Journal of the Turkish Nephrology Society. 1997; 3-4: 131-135.
31. Laakkonen J, Kallio-Kokko H, Oktem MA ve ark. Serological survey for viral pathogens in Turkish rodents. J Wildl Dis. 2006; 42: 672-6.
32. Çelebi G, Öztoprak N, Öktem İMA ve ark. Dynamics of Puumala hantavirus outbreak in Black Sea Region, Turkey. Zoonoses Public Health. 2019; 66: 783-797.
33. Ertek M, Buzgan T. An outbreak caused by hantavirus in the Black Sea region of Turkey, January-May 2009. Euro Surveill. 2009; 21: 14: 19214.
34. Oktem IM, Uyar Y, Dincer E ve ark. Dobrava-Belgrade virus in Apodemus flavicollis and A. uralensis mice, Turkey. Emerg Infect Dis. 2014; 20: 121-125.
35. Sevencan F, Gözalan A, Uyar Y ve ark. Serologic Investigation of Hantavirus Infection in Patients with Previous Thrombocytopenia, and Elevated Urea and Creatinine Levels in an Epidemic
Region of Turkey. Jpn J Infect Dis. 2015; 68: 488-93.
36. Polat C, Ergin Ç, Akkaya Y ve ark. Investigation of Orthohantavirus Seroprevalence in Northern Rural Areas of Denizli Province, Turkey. Jpn J Infect Dis. 2020; 22:73: 201-204.
37. Oncul O, Atalay Y, Onem Y, ve ark. Hantavirus infection in Istanbul, Turkey. Emerg Infect Dis. 2011; 17: 303-4.
38. Polat C, Sironen T, Plyusnina A ve ark. Dobrava hantavirus variants found in Apodemus flavicollis mice in Kırklareli Province, Turkey. J Med Virol. 2018; 90: 810-818.
39. Erdin M, Polat C, Smura T ve ark. Phylogenetic Characterization of Orthohantavirus dobravaense (Dobrava Virus). Emerg Infect Dis. 2024; 30: 779-782.
40. Polat C, Ergünay K, Irmak S ve ark. A novel genetic lineage of Tula orthohantavirus in Altai voles (Microtus obscurus) from Turkey. Infect Genet Evol. 2019; 67: 150-158.
41. Erdin M, Smura T, Kalkan KK ve ark. Detection of divergent Orthohantavirus tulaense provides insight into wide host range and viral evolutionary patterns. Npj Viruses. 2024; 2: 62.
42. Mackow ER, Gavrilovskaya IN. Hantavirus regulation of endothelial cell functions. Thromb Haemost. 2009; 102: 1030-41.
43. Mustonen J, Outinen T, Laine O ve ark. Kidney disease in Puumala hantavirus infection. Infect Dis (Lond). 2017 ; 49: 321-332.
44. Hallin GW, Simpson SQ, Crowell RE ve ark. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit Care Med. 1996; 24: 252-8.
45. Hjelle B, Jenison S, Torrez-Martinez N ve ark. Rapid and specific detection of Sin Nombre virus antibodies in patients with hantavirus pulmonary syndrome by a strip immunoblot assay
suitable for field diagnosis. J Clin Microbiol. 1997; 35: 600-8.
46. Kramski M, Meisel H, Klempa B ve ark. Detection and typing of human pathogenic hantaviruses by real-time reverse transcription-PCR and pyrosequencing. Clin Chem. 2007; 53: 1899-905.
47. Vial PA, Valdivieso F, Ferres M, Riquelme R, Rioseco ML, Calvo M, Castillo C, Díaz R, Scholz L, Cuiza A, Belmar E, Hernandez C ve ark. Hantavirus Study Group in Chile. High-dose intra-
venous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial. Clin Infect Dis. 2013; 57: 943-51.
48. Huggins JW, Hsiang CM, Cosgriff TM ve ark. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal synd-
rome. J Infect Dis. 1991; 164: 1119-27.
49. Duchin JS, Koster FT, Peters CJ, ve ark. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N Engl J Med.
1994; 7;330: 949-55.
50. Cho HW, Howard CR, Lee HW. Review of an inactivated vaccine against hantaviruses. Intervirology. 2002; 45: 328-33.
51. Buchmeier, M. J., de la Torre, J. C., & Peters, C. J. (2007). Arenaviridae: the viruses and their replication. In Fields Virology (5th ed., pp. 1791–1827). Lippincott Williams & Wilkins.
52. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis. 1987; 155: 437-44.
53. Enria DA, Briggiler AM, Sánchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 2008; 78: 132-9.